Fused purine derivatives
    1.
    发明授权
    Fused purine derivatives 失效
    融合嘌呤衍生物

    公开(公告)号:US07005430B2

    公开(公告)日:2006-02-28

    申请号:US10149423

    申请日:2000-12-22

    CPC分类号: C07D487/14

    摘要: A condensed purine derivative represented by Formula (I): wherein X—Y-Z represents R1N—C═O or N═C—W, R2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X—Y-Z represents R1aN—C═O and R2 represents a substituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a halogen atom, a lower alkylthio group, —NR7R8, —CO2H, a lower alkoxycarbonyl group, —COHal, —CONR9R10 or —CHO, V2 may represent a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group; or a pharmacologically acceptable salt thereof.

    摘要翻译: 由式(I)表示的稠合嘌呤衍生物:化学式id =“CHEM-US-00001”num =“000”

    Fused pyrimidine derivatives
    2.
    发明申请
    Fused pyrimidine derivatives 审中-公开
    融合嘧啶衍生物

    公开(公告)号:US20060252780A1

    公开(公告)日:2006-11-09

    申请号:US10554254

    申请日:2004-04-23

    IPC分类号: A61K31/519 C07D487/14

    CPC分类号: C07D487/14

    摘要: A fused pyrimidine derivative is presented. The derivatie has an insulin secretion stimulating activity represented by Formula (I): {wherein R1 represents a hydrogen atom, lower alkyl, or the like; n represents an integer of 0 to 3; and X1 and X2 may be the same or different and each represents a hydrogen atom, lower alkyl, or the like; and formula (II): represents formula (III): [wherein X—Y—Z represents R2C═CR3—NR4 (wherein R2, R3 and R4 may be the same or different and each represents a hydrogen atom, lower alkyl, or the like)]}, or a pharmaceutically acceptable salt thereof.

    摘要翻译: 提出了一种稠合的嘧啶衍生物。 衍生物具有由式(I)表示的胰岛素分泌刺激活性:其中R 1表示氢原子,低级烷基等; n表示0〜3的整数, X 1和X 2可以相同或不同,各自表示氢原子,低级烷基等; 和式(II):表示式(III):[其中XYZ表示R 2 C-CR 3 -NR 4(其中R' O 2,R 3和R 4可以相同或不同,各自表示氢原子,低级烷基等)]}, 或其药学上可接受的盐。

    Remedies for diabetes
    3.
    发明授权
    Remedies for diabetes 失效
    糖尿病补救

    公开(公告)号:US06489331B1

    公开(公告)日:2002-12-03

    申请号:US09719570

    申请日:2001-04-09

    IPC分类号: A61K3152

    摘要: A medicament for the therapeutic treatment of diabetes which comprises as an active ingredient a compound represented by the general formula (I): wherein R1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, R2 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, R3 represents a hydrogen atom, a lower alkyl group or a substituted or unsubstituted aralkyl group, X1 and X2 independently represent a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and the symbol “n” represents an integer of from 0 to 3, or a physiologically acceptable salt thereof.

    摘要翻译: 一种用于治疗糖尿病的药物,其包含作为活性成分的由通式(I)表示的化合物:其中R 1表示氢原子,低级烷基,取代或未取代的芳基或取代或未取代的芳族 杂环基,R2表示氢原子,低级烷基,取代或未取代的芳烷基,取代或未取代的芳基或取代或未取代的芳香族杂环基,R3表示氢原子,低级烷基或取代 或未取代的芳烷基,X 1和X 2独立地表示氢原子,低级烷基,取代或未取代的芳烷基或取代或未取代的芳基,符号“n”表示0〜3的整数,或 其生理上可接受的盐。